Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib

doi:10.1186/s12885-022-09683-1

HFCAS OpenIR

	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib
	Jin, Ying 1,2,3,4; Lin, Chen 2,3; Shi, Xun 2,3; He, Qiong 2,3; Yan, Junrong 5; Yu, Xinmin 2,3; Chen, Ming 1,6,7
	2022-05-28
发表期刊	BMC CANCER
通讯作者	Yu, Xinmin(yuxm@zjcc.org.cn) ; Chen, Ming(chenming@zjcc.org.cn)
摘要	Background Although with the impressive efficacy, several patients showed intrinsic resistance or an unsatisfactory response to Osimertinib. We aim to explore the impact of clinical and molecular features on efficacy and outcome of patients with EGFR T790M-mutation non-small cell lung cancer (NSCLC) receiving second-line Osimertinib. Methods Patients with EGFR T790M-mutant NSCLC who had acquired resistance to the first-generation EGFR TKI and then received Osimertinib as second-line treatment were included. Patients' demographic and clinical information, as well as molecular data were extracted from electronic medical records. The impact of clinical and molecular features on treatment response and patients' outcome were assessed. Results Among the 99 patients, 60 patients were tissue/pleural effusion T790M positive and 69 patients were plasma positive with a median PFS of 12.1 m and 9.9 m (P = 0.25), respectively. In addition, median PFS were similar between patients of plasma T790M + and patients of plasma T790M- (P = 0.94). The Pearson correlation test showed no significant relationship between plasma T790M abundance and PFS (r = 0.074, P = 0.546). In subgroup analyses, PFS was significantly improved in elder patients (P = 0.009) and patients with longer PFS to the first-generation EGFR TKI (P = 0.0008), while smokers tended to have worse PFS compared with non-smokers (P = 0.064). PARP1 mutant-type patients had a worse PFS compared with wild-type group (P = 0.0003). Patients with MYC amplification also had a worse PFS than MYC wild-type patients (P = 0.016). A significant PFS shrinkage was observed in TMB-High group as 6.77 m, compared with 19.10 m in TMB-Low group. The multivariate Cox analysis revealed that years >= 65 was an independent positive feature for PFS, while PARP1 mutation and TMB-H were negative features for PFS. Conclusion In conclusion, our findings in this study demonstrated that clinical and molecular features can be served as predictive biomarkers to stratify patients with EGFR T790M-mutant NSCLC receiving second-line Osimertinib.
关键词	Clinical and molecular features Efficacy and outcome EGFR T790M mutation Non-small-cell lung cancer Osimertinib
DOI	10.1186/s12885-022-09683-1
关键词[WOS]	OPEN-LABEL ; 1ST-LINE TREATMENT ; ACQUIRED-RESISTANCE ; CHEMOTHERAPY ; MULTICENTER ; GEFITINIB ; ERLOTINIB ; AFATINIB ; THERAPY
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[81702248]
项目资助者	National Natural Science Foundation of China
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000801165100002
出版者	BMC
引用统计	被引频次：2[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/131120
专题	中国科学院合肥物质科学研究院
通讯作者	Yu, Xinmin; Chen, Ming
作者单位	1.Soochow Univ, Affliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China 2.Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 3.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Zhejiang, Peoples R China 4.Zhejiang Key Lab Radiat Oncol, Hangzhou 310022, Zhejiang, Peoples R China 5.Nanjing Geneseeq Technol Inc, Med Dept, Nanjing 210000, Peoples R China 6.Sun Yat Sen Univ, Canc Ctr, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China 7.Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
推荐引用方式 GB/T 7714	Jin, Ying,Lin, Chen,Shi, Xun,et al. Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib[J]. BMC CANCER,2022,22.
APA	Jin, Ying.,Lin, Chen.,Shi, Xun.,He, Qiong.,Yan, Junrong.,...&Chen, Ming.(2022).Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.BMC CANCER,22.
MLA	Jin, Ying,et al."Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib".BMC CANCER 22(2022).